Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Corea y enfermedad de Huntington

4872 ARTíCULOS , VIENDO DEL 4246 AL 4260

PUBMED

Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.

Safren N, El Ayadi A, Chang L, Terrillion CE, Gould TD, Boehning DF, Monteiro MJ.

PLoS One. 2014 Jan 27;9(1):e87513. doi: 10.1371/journal.pone.0087513.

0

0

0

PUBMED

Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease.

Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR, Thomas EA.

Hum Mol Genet. 2012 Jul 15;21(14):3097-111. doi: 10.1093/hmg/dds132.

0

0

0

PUBMED

Increased oxidative stress and CaMKII activity contribute to electro-mechanical defects in cardiomyocytes from a murine model of Huntington's disease.

Joviano-Santos JV, Santos-Miranda A, Botelho AFM, de Jesus ICG, Andrade JN, de Oliveira Barreto T, Magalhães-Gomes MPS, Valadão PAC, Dos Santos Cruz J, Melo MM, Guatimosim S, Guatimosim C.

FEBS J. 2018 Nov 19. doi: 10.1111/febs.14706. [Epub ahead of print]

0

0

0

PUBMED

Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.

Carbo M, Brandi V, Pascarella G, Staid DS, Colotti G, Polticelli F, Ilari A, Morea V.

Int J Mol Med. 2019 Oct 15. doi: 10.3892/ijmm.2019.4373. [Epub ahead of print]

0

0

0

PUBMED

Mitochondrial cristae remodelling is associated with disrupted OPA1 oligomerisation in the Huntington's disease R6/2 fragment model.

Hering T, Kojer K, Birth N, Hallitsch J, Taanman JW, Orth M.

Exp Neurol. 2017 Feb;288:167-175. doi: 10.1016/j.expneurol.2016.10.017.

0

0

0

PUBMED

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Ferreira JJ, Mahlknecht P, Tumas V, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee o

Mov Disord. 2016 Oct;31(10):1466-1478. doi: 10.1002/mds.26675. Review.

0

0

0

PUBMED

Thiol-disulfide Oxidoreductases TRX1 and TMX3 Decrease Neuronal Atrophy in a Lentiviral Mouse Model of Huntington's Disease.

Fox J, Lu Z, Barrows L.

PLoS Curr. 2015 Nov 6;7. pii: ecurrents.hd.b966ec2eca8e2d89d2bb4d020be4351e. doi: 10.1371/currents.hd.b966ec2eca8e2d89d2bb4d020be4351e. Erratum in: PLoS Curr. 2016;8. pii: ecurrents.hd.30bdfed3d88457fd605cb8f95fba29b5. doi: 10.1371/currents.hd.30bdfed3d88457fd605cb8f95fba29b5.

0

0

0

PUBMED

Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.

Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, Offen D.

Exp Neurol. 2012 Apr;234(2):417-27. doi: 10.1016/j.expneurol.2011.12.045.

0

0

0

PUBMED

The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington's disease.

Wanker EE, Ast A, Schindler F, Trepte P, Schnoegl S.

J Neurochem. 2019 Nov;151(4):507-519. doi: 10.1111/jnc.14853. Epub 2019 Sep 15. Review.

0

0

0

PUBMED

Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.

Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P.

Mol Ther Nucleic Acids. 2016 Mar 22;5:e297. doi: 10.1038/mtna.2016.7.

0

0

0

PUBMED

Huntington's disease and behavioral dyscontrol.

Chua SM, Lee TS.

J Neuropsychiatry Clin Neurosci. 2010 Fall;22(4):451-f.e10-451.e11. doi: 10.1176/appi.neuropsych.22.4.451-f.e10. No abstract available.

0

0

0

PUBMED

Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington's disease.

Andersen JV, Skotte NH, Aldana BI, Nørremølle A, Waagepetersen HS.

Cell Mol Life Sci. 2019 Mar 4. doi: 10.1007/s00018-019-03051-2. [Epub ahead of print]

0

0

0

PUBMED

Anesthetic management of patients with Huntington disease.

Kivela JE, Sprung J, Southorn PA, Watson JC, Weingarten TN.

Anesth Analg. 2010 Feb 1;110(2):515-23. doi: 10.1213/ANE.0b013e3181c88fcd.

0

0

0

PUBMED

Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington's disease models.

Smalley JL, Breda C, Mason RP, Kooner G, Luthi-Carter R, Gant TW, Giorgini F.

J Mol Med (Berl). 2016 Feb;94(2):235-45. doi: 10.1007/s00109-015-1344-5.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy